Decision catalogueModality
Identity before mechanism in extracellular vesicle packages
Decision problem
What must be true about vesicle identity and controls before mechanism claims can carry a check?
Thesis
If cargo, purity, and functional controls are underspecified, mechanism narratives are metaphors—not something you can underwrite.
Extracellular vesicle and exosome packages frequently arrive with regenerative or delivery language that outruns characterization. Buyers then debate mechanism while the product definition is still elastic.
The review opens on identity: what defines the product lot, which purified or conditioned-media controls falsify a non-specific effect, and which analytical methods could support the stated development path. Mechanism language that cannot survive those questions does not belong at the center of the memo.
Batch-to-batch reproducibility is often the translational claim itself. Missing release logic is a financing gate — the raise either buys a path to closed identity, or it buys unresolved vesicle science.
Claim map
Claims a Decision Sprint memo would force onto the page
- Product identity is defined tightly enough to underwrite the next study
- Functional claims survive non-specific vesicle or conditioned-media controls
- Analytical methods can support the stated regulatory and CMC path
Decision triggers
Outputs from the claim test that should change the conversation
- Mechanism stated as product without assay-linked identity
- Batch characterization gaps that break translational read-through
- Regulated path assumed without an explicit control-strategy discussion
Sources
Related in the catalogue
- Prior work · Extracellular vesicles
Anonymized account of decision pressure in this modality class.
- Method · how a Decision Sprint works
How claims are pulled from the thesis, checked against published evidence, and written for the investment call.
- When potency and comparability decide the cell therapy raise
Is the next round buying a clinical claim, or an unresolved potency and comparability project?
- 361 language is not a free option on tissue technologies
Which claims stay inside a lighter regulatory path — and which processing moves reclassify risk?
- Claim maps beat generic diligence checklists for seed decisions
How should a lean team test science under a short deal deadline?
Facing this cut on a live $1–10M package?
Scope a Decision Sprint for one opportunity under your deal deadline—claim map, risk register, management questions, and partner briefing.